Form 4: RA Capital Management Acquires Stock Options in Cidara Therapeutics

RA Capital Management and related parties have acquired stock options in Cidara Therapeutics, vesting over a three-year period.

Summary

• RA Capital Management, L.P., along with related entities and individuals, has reported the acquisition of stock options in Cidara Therapeutics, Inc.
• The options, totaling 22,200 shares, were acquired on January 3, 2025, at an exercise price of $26.62.
• The options vest over a three-year period, with one-third vesting on January 3, 2026, and the remaining two-thirds vesting in equal monthly installments until January 3, 2028.
• The reporting parties include RA Capital Management, L.P., RA Capital Healthcare Fund LP, Peter Kolchinsky, and Rajeev M. Shah, all of whom are associated with RA Capital Management.
• These individuals and entities are also listed as directors and 10% owners of Cidara Therapeutics.
• The options are held indirectly, with Joshua Resnick, a Partner of the Adviser, holding the option for the benefit of the Fund.

Sentiment

Score: 7

Explanation: The acquisition of stock options by a major shareholder is generally a positive sign, indicating confidence in the company's future. However, the document is a standard regulatory filing and does not provide any specific information about the company's performance or outlook.

Positives

• The acquisition of stock options by a major shareholder like RA Capital Management could be seen as a positive sign of confidence in Cidara Therapeutics' future prospects.
• The vesting schedule encourages long-term commitment from RA Capital Management.

Risks

• The document does not provide any information about the current market price of Cidara Therapeutics stock, so it is not possible to assess the value of the options.
• The vesting schedule means that the full benefit of the options will not be realized for several years.

Management Comments

• RA Capital Management, L.P., the Adviser, disclaims beneficial ownership of the reported securities, except to the extent of its pecuniary interest.
• Joshua Resnick is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund to the Adviser.

Industry Context

This filing is a standard SEC Form 4, which is used to report changes in beneficial ownership of securities by company insiders. It is common for investment firms like RA Capital Management to acquire stock options in companies they invest in.

Comparison to Industry Standards

• The vesting schedule of the stock options is typical for executive and director compensation packages.
• The reporting of beneficial ownership is consistent with SEC regulations for insider trading.

Stakeholder Impact

• The acquisition of stock options by RA Capital Management could be viewed positively by shareholders, potentially increasing confidence in the company.
• The vesting schedule may incentivize RA Capital Management to support the long-term success of Cidara Therapeutics.

Key Dates

Keywords

stock options, RA Capital Management, Cidara Therapeutics, beneficial ownership, vesting, directors, 10% owner